Andexanet alfa reverses blood thinning of rivaroxaban
Full results from a Phase III study examining Portola Pharmaceutical's developmental compound andexanet alfa found it rapidly and significantly reversed the anticoagulant effects of rivaroxaban. These results will be presented at the American College of Cardiology meeting March 16.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063